




# Clinical and neuropsychological features of behavioral variant frontotemporal dementia and phenocopy syndrome



Cinzia Bussè<sup>1,2</sup>, Sara Pompanin<sup>2</sup>, Silvia Zanettin<sup>2</sup>, Giovanni Zorzi<sup>2</sup>, Federica Fragiaco<sup>2</sup>, Giorgio Pigato<sup>2</sup>, Annachiara Cagnin<sup>2,3</sup>

<sup>1</sup> Department of Neurosciences, Psychology, Pharmacology and Child Health, NEUROFARBA, University of Florence

<sup>2</sup> Department of Neurosciences, University of Padua, Padova, Italy

<sup>3</sup> IRCCS; San Camillo Hospital Foundation, Venice, Italy

**Introduction:** The core features of **behavioural frontotemporal dementia (bvFTD)** (Rascovsky, 2011) are early behavioral and executive deficits, with insidious changes in personality and behaviour, often occurring in the absence of cognitive impairment [Figure 1]. Some individuals who meet diagnostic criteria for bvFTD have a very slow disease course (over decades) with slow progression of cognitive impairment and normal MRI and positron emission tomography (PET) studies. They are classified as having **bvFTD phenocopy syndrome (bvFTD-PS)**. Considering that clinical symptoms and cognitive impairment may overlap in bvFTD and in bvFTD-PS (Kipps, 2010), a great attention has been recently focused on the differences obtained with a clinical and cognitive assessment.

**Aim:** To study the clinical and cognitive variables differentiating **bvFTD** patients and **bvFTD-PS**.

**Materials and methods:** 33 patients (13 men and 20 women, mean age 65.3 ±9.4 years, mean disease duration 4 ±4.0 years) with a diagnosis of possible bvFTD according to Raskovsky criteria were recruited in the study. Each patient underwent a full neurological evaluation and an **extensive cognitive battery**. Behavioural assessments using the Neuropsychiatric Inventory (**NPI**) and the Repetitive Behaviours Subscale (**RBS**) were administrated. Clinical, demographic and cognitive data was analyzed with the Statistical Package for Social Science (SPSS 21.0) using t-test with Bonferroni correction and  $\chi^2$  for categorical variables ( $p=0.05$ ).

**Results:** bvFTD patients were younger than bvFTD-PS patients ( $p=0.009$ ) [Table 1]. Total NPI and RBS scores were similar in the two groups. However, in bvFTD **NPI-apathy** score and **eating/dietary changes** score were higher ( $p=0.005$  and  $p=0.008$  respectively) than in bvFTD-PS, while in bvFTD-PS **NPI-anxiety** score was greater ( $p=0.034$ ). In the RBS scale subitems, **obsessive counting** was more frequent and severe in bvFTD ( $p=0.05$ ). As for cognitive differences, although the MMSE score was similar, a more impaired **semantic and phonemic fluency** (phonemic:  $p=0.005$ ; semantic:  $p=0.010$ ), as well as deficit of working memory (**immediate prose memory test**:  $p=0.002$ ) were detected in the bvFTD group [Table 3].

**Figure 1.**  
Diagnostic criteria for bvFTD proposed by Rascovsky et al. (2011) (from Lanata et al. 2015)

<b>Possible bvFTD</b>	Three or more of the following 6 features: <ul style="list-style-type: none"> <li>▶ Early behavioural disinhibition</li> <li>▶ Early apathy or inertia</li> <li>▶ Early loss of sympathy or empathy</li> <li>▶ Early perseverative, stereotyped or compulsive/ritualistic behaviours</li> <li>▶ Hyperorality and dietary changes</li> <li>▶ Deficits in executive function with relative sparing of episodic memory and visuospatial skills (as determined by structured neuropsychological testing)</li> </ul>
<b>Probable bvFTD</b>	Possible bvFTD AND evidence of BOTH the following: <ul style="list-style-type: none"> <li>▶ Significant functional decline</li> <li>▶ Frontal and/or anterior temporal lobe atrophy on MRI or CT, or frontal and/or temporal hypoperfusion or hypometabolism on PET or SPECT</li> </ul>
<b>Definite bvFTD</b>	Possible OR probable bvFTD AND evidence of EITHER of the following: <ul style="list-style-type: none"> <li>▶ Histopathological changes consistent with FTLD on biopsy or autopsy</li> <li>▶ Presence of known FTLD pathogenic genetic mutation</li> </ul>

**Table 1.**  
Demographic features of study population subdivided in bvFTD group and bvFTD-PS group. Age at the study, age at onset and disease duration are expressed in years (yr.); MMSE score is indicated as raw score (r.s.).

Demographic data	bvFTD n=19	bvFTD-PS n=11	p=
Mean age (yr.)	62.6 ±8.4	70.5 ±6.7	0.009
Gender M/F (% female)	8/11 (57.9%)	5/6 (54.5%)	0.858
Age at onset (yr.)	58.9 ±9.3	66.2 ±7.1	0.024
Disease duration (yr.)	3.7 ±3.8	4.4 ±4.2	0.688
MMSE score (r.s.)	21.4 ±5.8	22.9 ±5.8	0.489

**Table 2.**  
Clinical features at disease onset in the two populations.

Clinical features (disease onset)	bvFTD n=19	bvFTD-PS n=11	p=
Positive family history	8 (42.1%)	3 (27.3%)	0.416
Behavioural symptoms at disease onset			
disinhibition	5 (26.3%)	7 (63.6%)	<b>0.044</b>
apathy	6 (31.6%)	0	<b>0.037</b>
OCD symptoms	4 (21.0%)	0	0.102
decreased speech output	3 (15.8%)	0	0.164
psychosis	1 (5.3%)	3 (18.2%)	0.255
cognitive executive deficits	1 (5.3%)	3 (18.2%)	0.255
Motor symptoms at disease onset	5 (26.3%)	4 (36.4%)	0.562

**Table 3.**  
Summary of the neuropsychological battery in the two groups. RAVLT: Rey Auditory Verbal Learning Test; TMT: Trail Making Test; FAB: Frontal Assessment Battery; ROCF: Rey-Osterrieth complex figure.

Neuropsychological assessment	bvFTD n=15 (78.9%) mean raw score ±SD	bvFTD-PS n=9 (81.8%) mean raw score ±SD	p=
Demographic feature			
Age (yr.)	62.5 ±8.6	70.6 ±6.7	0.020
Gender (M/F) (female %)	7/8 (42.1%)	5/4 (36.4%)	0.673
Education (yr.)	10.3 ±4.7	7.9 ±2.8	0.130
MMSE	22.9 ±3.6	24.7 ±4	0.286
Digit Span Forward	4.4 ±1.1	4.4 ±2.4	0.976
Digit Span Backward	3.2 ±1.4	2.3 ±1.3	0.147
Immediate Prose Memory	4.6 ±3.3	9.7 ±2.3	<b>0.002</b>
Delayed Prose Memory	5.7 ±4.6	9.7 ±3.4	<b>0.053</b>
RAVLT Immediate Recall	24.1 ±9.9	32.0 ±12.9	0.324
RAVLT Delayed Recall	3.7 ±2.9	6.3 ±2.6	0.162
Attentional Matrix	37.2 ±13.0	42.4 ±12.1	0.348
TMT A time	103.6 ±81.1	81.6 ±40.2	0.395
TMT B time	227.6 ±161.7	267.0 ±147.1	0.630
FAB	10.3 ±4.1	12.5 ±1.3	0.152
Clock Test	9.6 ±7.5	5.2 ±3.7	0.173
Phonemic Fluency	12.5 ±10.7	26.1 ±9.1	<b>0.005</b>
Semantic Fluency	18.7 ±10.6	33.5 ±11.6	<b>0.010</b>
ROCF Copy	27.4 ±7.9	24.5 ±10.7	0.570
ROCF Recall	3.5 ±4.3	12.6 ±7.4	0.085

**Conclusion:** Patients with **bvFTD** were **more apathetic and less anxious** respect to bvFTD-PS patients. **Dietary/eating changes** may be specific markers of bvFTD, while disinhibition, lack of empathy and stereotypes are shared features of the two groups. **Working memory** e **verbal fluency deficits** could be cognitive variables associated more to bvFTD than its phenocopy.

**Acknowledgements:** The current work is supported by AIRAzh Onlus-COOP Italia